this speaks for itself
SAN DIEGO, Aug 21, 2014 (GLOBE NEWSWIRE via COMTEX) --
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Cytori Therapeutics, Inc. breached their fiduciary duties to shareholders. Cytori is a cell therapy company that develops cell therapies based on autologous adipose-deprived regenerative cells to treat cardiovascular disease and other medical conditions.
View this press release on the law firm's Shareholder Rights Blog:
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, , or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Why are you here ,just to say i told you so. You like to see others suffer ? why not crawl back underneath the rock from which you came.
I would like to see all insiders buying. If they don't buy they why would anyone else. Time to put up or shut up. They have milked the cash cow and it 's running dry.
truth pumpers on this board can't handle the truth wear the thumbs down as a badge of honor
ADRC not sure why anyone would not understand your reasoning. Below says it all, Not to mention that management was not at all forthcoming about trial delay, but have they really ever been about anything.
Ascendiant Capital lowered its Buy rating to Hold on Cytori Therapeutics (NASDAQ: CYTX).
Ascendiant Capital mentioned that the ATHENA trials were put on clinical hold:
“The Company has announced that it has placed enrollment in the ATHENA and ATHENA II trials on clinical hold. This decision was based on a safety review that reported cerebrovascular events had occurred in 3 patients enrolled in the ATHENA study.”
Ascendiant Capital also mentioned that a secondary capital offering will be necessary for Cytori to stay solvent:
“Cytori Therapeutics ended Q1 2014 with $12.8 MM in cash. This compares to $22 MM at the end of 2013. We believe that the company will need to raise additional cash in the future. Now that the ATHENA studies are on hold, we would anticipate that R&D expense will decrease, which should reduce the cash burn from operation, which lately has been around $9 MM per quarter.”
Cytori Therapeutics were last trading at $1.67, down 20.48 percent.
Chuck, you should not be left to speculate. This announcement should have been accompanied with a conference call from Marc explaining what is going on. While there is a call scheduled for Mon in my opinion that does suffice. If your speculation on Athena holds any water, then it just becomes another example of managements incompetence, and it's trial by error management approach. It is especially disappointing as we were specifically told that management was going to focus on trials/projects that would provide the best return to the company . This was done so that they could use limited funds in the most productive way. I hardly think this is productive,nor do I feel that Marc is being true to his comment about better communication with shareholders. With information we could all decide if this in fact a buying opportunity or the beginning of the end. The stock market today has become a casino so anyone blindly buying today is gambling. I've lost enough and would like to know should I fold em ,hold em, or draw more cards . I would speculate that much of the buying is short's covering and realizing there tremendous gains.
Saad felt that share price would be above exercise price and that warrants would be exercised. He shared this thought with investors holding huge positions. Wrong again. This management team will stop at nothing when it comes to misleading shareholders. Lets see annual meeting on Monday and not a mention. They just must have found out today. Can't wait to see what surprises they unleash on us during Monday's conference call. Just another mis step, another do over. As we have been told that they would focus on areas that would generate revenue and this is where they would invest money. Cardiac was to be the big money maker,guess not. Next to go by the wayside Sports medicine applications,followed by BARDA disappointment. Congratulations guys, did not think you could be worse then CC but your doing your best.
Smart move getting approvals on your compensation packages at the AM as well. No wonder you took no questions. I am just sick over this entire situation. Shout out to Lloyd Dean , on the double down, this is definitely not 10 x's my wildest dreams but it has become my worst nightmare. Guess I heard you wrong.
Shorts are celebrating tonight and sharks smelling blood for tomorrow.
Okyanos may be dead before it gets started. Checked out Trillo and building is being offered for conversion to a hotel. Can't see anyone traveling to the Bahamas for a treatment that is very suspect. Investors who have millions at stake there must be very happy. So much for revenues being generated for Cytori through sales of consumables.
Have you been in a coma for the past 3 weeks or so, this is old news that was addressed by the company the day it happened. While the reasoning was rather lame, which was that he did not want to travel to US 4 times a year, he certainly should have though about that before he accepted the position.
OKYO (AP) - A senior Japanese scientist embroiled in a stem-cell research scandal died Tuesday in an apparent suicide, police said.
Yoshiki Sasai, who supervised and co-authored stem-cell research papers that had to be retracted due to falsified contents, was found suffering from cardiac arrest at the government-affiliated science institute RIKEN in Kobe, in western Japan, according to Hyogo prefectural police. Sasai, 52, was deputy chief of RIKEN's Center for Developmental Biology.
A security guard found him with a rope around his neck, according to RIKEN. Sasai was rushed to a hospital, but was pronounced dead two hours later.
Police and RIKEN said Sasai left what appeared to be suicide notes, but refused to disclose their contents.
RIKEN spokesman Satoru Kagaya told a news conference that Sasai had three letters with him, each addressed to Haruko Obokata, a co-author of the research papers, as well as senior members of RIKEN and fellow researchers. Two other notes addressed to RIKEN officials were on Sasai's secretary's desk.
Sasai's health had deteriorated over the past few months, and he had been receiving medical treatment. Kagaya said that Sasai started looking depressed in May, and that the two had hardly seen each other recently.
"He seemed exhausted. I could tell he was tired even on the phone," Kagaya said, referring to one of his last conversations with Sasai.
Sasai's team retracted the research papers from the British science journal Nature over Obokata's alleged malpractice, which she has contested. Retractions of papers in major scientific journals are extremely rare, and the scandal was a major embarrassment to Japanese scientific research.
Obokata was in shock when she heard the news of Sasai's death, Kagaya said. Obokata has been in and out of the hospital since the scandal due to her mental condition, and RIKEN has arranged a team of medical staff and colleagues to give her support, while monitoring her around the clock, he said.
In two papers published in Nature earlier this year, the researchers reported that they successfully transformed ordinary mouse cells into versatile stem cells by exposing them to a mildly acidic environment. Scientists hope to harness stem cells to grow replacement tissue for treating a variety of diseases.
RIKEN later held Obokata, a main author of the research, responsible for falsifying data. The investigation also focused on Sasai and two other employees, though the three were not accused of research misconduct.
Sasai had said he was "deeply ashamed" over the problems with the papers.
We will wake up to the news that a company has monetized opportunities in sports medicine all right,however, I fear it won't be Cytori. CC failed in his quest to land a deal in Europe in his last ditch effort to go out with a positive. A share price reflects the future value of a company so, the markets currents believe such is the case.
There is most likely not a single investor who reads this board who did not vote against the BOD. It doesn't matter votes controlled from the inside so your wasting your breath.
Surprised you are so short sighted Street. While FDA approval needed for US, what about Europe where there is nothing keeping this technology from being used. Cytori claimed that with breast reconstruction for example that sales in Europe alone could have Cytori operating at break even. That was BS and no revenue has been generated. Back to sports medicine, big talk about study in Spain but no deal materialized and CC was focusing on exactly that in his final months as a consultant. Giving Cytori a pass on nothing happening as of yet where technology can be used and blaming on FDA and giving management a pass is ridiculous..
Wanted to extend my congratulations to the Cytori management team as we approach tomorrows annual meeting. Last year on this date Cytori was trading at the anemic pps of $2.65. After a year you have manged to create shareholder value by lowering the PPS to $2.15 loosing .50 in value and further diluting shareholder value , and increasing my losses Way to go you should be proud of yourselves and I'm sure that Mr. Rickey will see it fit to award you all more shares and give you raises for the bang up job you have done. Special thanks,to Clyde Sores who has manged to generate lower sales this year vs. last for the same time period while earning additional options and an increase in salary. Awesome job fellas awesome job. You wouldn't last a year in my industry with that type of performance.
That statement is ridiculous. If warrants expire worthless then that is how the market works. There is absolutely zero basis for legal action. These are warrants that are traded on the open market not insider warrants like the May warrants. Saad will do whatever he can to see that Cytori is in the money so they are exercised but that will take actual results that move the pps not hocus pocus. Cytori has definitely been a results oriented company .